This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.

Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.


1llt

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
-
[[Image:1llt.gif|left|200px]]
+
{{Seed}}
 +
[[Image:1llt.png|left|200px]]
<!--
<!--
Line 9: Line 10:
{{STRUCTURE_1llt| PDB=1llt | SCENE= }}
{{STRUCTURE_1llt| PDB=1llt | SCENE= }}
-
'''BIRCH POLLEN ALLERGEN BET V 1 MUTANT E45S'''
+
===BIRCH POLLEN ALLERGEN BET V 1 MUTANT E45S===
-
==Overview==
+
<!--
-
Specific allergy vaccination is an efficient treatment for allergic disease; however, the development of safer vaccines would enable a more general use of the treatment. Determination of molecular structures of allergens and allergen-Ab complexes facilitates epitope mapping and enables a rational approach to the engineering of allergen molecules with reduced IgE binding. In this study, we describe the identification and modification of a human IgE-binding epitope based on the crystal structure of Bet v 1 in complex with the BV16 Fab' fragment. The epitope occupies approximately 10% of the molecular surface area of Bet v 1 and is clearly conformational. A synthetic peptide representing a sequential motif in the epitope (11 of 16 residues) did not inhibit the binding of mAb BV16 to Bet v 1, illustrating limitations in the use of peptides for B cell epitope characterization. The single amino acid substitution, Glu(45)-Ser, was introduced in the epitope and completely abolished the binding of mAb BV16 to the Bet v 1 mutant within a concentration range 1000-fold higher than wild type. The mutant also showed up to 50% reduction in the binding of human polyclonal IgE, demonstrating that glutamic acid 45 is a critical amino acid also in a major human IgE-binding epitope. By solving the three-dimensional crystal structure of the Bet v 1 Glu(45)-Ser mutant, it was shown that the change in immunochemical activity is directly related to the Glu(45)-Ser substitution and not to long-range structural alterations or collapse of the Bet v 1 mutant tertiary structure.
+
The line below this paragraph, {{ABSTRACT_PUBMED_12960334}}, adds the Publication Abstract to the page
 +
(as it appears on PubMed at http://www.pubmed.gov), where 12960334 is the PubMed ID number.
 +
-->
 +
{{ABSTRACT_PUBMED_12960334}}
==About this Structure==
==About this Structure==
Line 30: Line 34:
[[Category: Allergen]]
[[Category: Allergen]]
[[Category: Pathogenesis related protein]]
[[Category: Pathogenesis related protein]]
-
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sat May 3 00:02:47 2008''
+
 
 +
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Wed Jul 2 21:23:43 2008''

Revision as of 18:23, 2 July 2008

Image:1llt.png

Template:STRUCTURE 1llt

BIRCH POLLEN ALLERGEN BET V 1 MUTANT E45S

Template:ABSTRACT PUBMED 12960334

About this Structure

1LLT is a Single protein structure of sequence from Betula pendula. Full crystallographic information is available from OCA.

Reference

Dominating IgE-binding epitope of Bet v 1, the major allergen of birch pollen, characterized by X-ray crystallography and site-directed mutagenesis., Spangfort MD, Mirza O, Ipsen H, Van Neerven RJ, Gajhede M, Larsen JN, J Immunol. 2003 Sep 15;171(6):3084-90. PMID:12960334

Page seeded by OCA on Wed Jul 2 21:23:43 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/1llt"
Personal tools